Kevin McGann, Accelus’s current president and CEO, has been appointed to the company’s Board of Directors. Prior to joining Accelus, McGann was vice president of sales at Stryker Spine, vice president of U.S. sales for Medtronic Spine & Biologics, and area director of sales for Kyphon. McGann, who joined Accelus in 2019, has also held the position of chief commercial officer.
Kevin McGann Appointed to Accelus Board of Directors
1 min read Premium comments
#accelusSecondary#kevinmcgann
McGann has also served as president of Lumenis, Inc. and was regional sales director for U.S. Surgical. McGann earned his B.S. in Business Administration from Villanova University.
As CEO, president and, now, board member, McGann will play the pivotal role in driving Accelus’s global and U.S. expansion. In terms of products, that expansion will rely heavily on the company’s Adaptive Geometry™ technology, used in the FlareHawk® Interbody Fusion System and its Toro®-L biplanar-expandable lateral implant as well as LineSider® Spinal System, a posterior screw system, and the BioNest® allograft bone matrix.
OTW asked McGan about Accelus’s Adaptive Geometry system and he explained, “Adaptive Geometry technology is a pivotal advancement in spine surgery. The brilliance of the engineering behind it cannot be overstated—allowing the implant to be inserted through a small incision and expanded within the interbody space.”
“The implant conforms to the endplate surface. While the credit for this innovation goes to the incredible engineers behind our FlareHawk and Toro products, since I have taken over as Chief Executive Office for Accelus, the company’s primary focus has been on sharing the benefits that Adaptive Geometry offers to spine surgeons and their patient care through our multidirectional expandable FlareHawk and Toro portfolios.”
“I’m excited to join the Accelus Board of Directors and know that it will allow me to create an even closer partnership with our Chairman, Alex Lukianov, and our esteemed board members. Our goal for the coming year is clear: to expand our reach and achieve extraordinary growth. With the focus and alignment, we have put into place, I am confident in our ability to execute this year.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.